Literature DB >> 4105313

Therapeutic trial of Imuran (azathioprine) in multiple sclerosis.

W S Cendrowski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4105313     DOI： 10.1111/j.1600-0404.1971.tb07480.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN： 0001-6314            Impact factor:   3.209


× No keyword cloud information.
  7 in total

1.  Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.

Authors:  E M Lance; M Kremer; J Abbosh; V E Jones; S Knight; P B Medawar
Journal:  Clin Exp Immunol       Date:  1975-07       Impact factor: 4.330

2.  The frequency of relapse in multiple sclerosis. A study based on 245 cases.

Authors:  F Lhermitte; R Marteau; J Gazengel; G Dordain; G Deloche
Journal:  Z Neurol       Date:  1973-08-29

3.  Long-term treatment of multiple sclerosis with azathioprine.

Authors:  W R Swinburn; L A Liversedge
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-02       Impact factor: 10.154

4.  Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study.

Authors:  P Theys; F Gosseye-Lissoir; P Ketelaer; H Carton
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

Review 5.  Azathioprine for multiple sclerosis.

Authors:  I Casetta; G Iuliano; G Filippini
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

6.  Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.

Authors:  R E Gonsette; L Demonty; P Delmotte
Journal:  J Neurol       Date:  1977-02-17       Impact factor: 4.849

Review 7.  Azathioprine. Safety profile in multiple sclerosis patients.

Authors:  L La Mantia; N Mascoli; C Milanese
Journal:  Neurol Sci       Date:  2007-12       Impact factor: 3.830
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.